Literature DB >> 22516442

Noninvasive programmed ventricular stimulation early after ventricular tachycardia ablation to predict risk of late recurrence.

David S Frankel1, Stavros E Mountantonakis, Erica S Zado, Elad Anter, Rupa Bala, Joshua M Cooper, Rajat Deo, Sanjay Dixit, Andrew E Epstein, Fermin C Garcia, Edward P Gerstenfeld, Mathew D Hutchinson, David Lin, Vickas V Patel, Michael P Riley, Melissa R Robinson, Wendy S Tzou, Ralph J Verdino, David J Callans, Francis E Marchlinski.   

Abstract

OBJECTIVES: The goal of this study was to evaluate the ability of noninvasive programmed stimulation (NIPS) after ventricular tachycardia (VT) ablation to identify patients at high risk of recurrence.
BACKGROUND: Optimal endpoints for VT ablation are not well defined.
METHODS: Of 200 consecutive patients with VT and structural heart disease undergoing ablation, 11 had clinical VT inducible at the end of ablation and 11 recurred spontaneously. Of the remaining 178 patients, 132 underwent NIPS through their implantable cardioverter-defibrillator 3.1 ± 2.1 days after ablation. At 2 drive cycle lengths, single, double, and triple right ventricular extrastimuli were delivered to refractoriness. Clinical VT was defined by comparison with 12-lead electrocardiograms and stored implantable cardioverter-defibrillator electrograms from spontaneous VT episodes. Patients were followed for 1 year.
RESULTS: Fifty-nine patients (44.7%) had no VT inducible at NIPS; 49 (37.1%) had inducible nonclinical VT only; and 24 (18.2%) had inducible clinical VT. Patients with inducible clinical VT at NIPS had markedly decreased 1-year VT-free survival compared to those in whom no VT was inducible (<30% vs. >80%; p = 0.001), including 33% recurring with VT storm. Patients with inducible nonclinical VT only, had intermediate 1-year VT-free survival (65%).
CONCLUSIONS: When patients with VT and structural heart disease have no VT or nonclinical VT only inducible at the end of ablation or their condition is too unstable to undergo final programmed stimulation, NIPS should be considered in the following days to further define risk of recurrence. If clinical VT is inducible at NIPS, repeat ablation may be considered because recurrence over the following year is high.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22516442     DOI: 10.1016/j.jacc.2012.01.026

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  16 in total

1.  Utility of ripple mapping for identification of slow conduction channels during ventricular tachycardia ablation in the setting of arrhythmogenic right ventricular cardiomyopathy.

Authors:  Shuanglun Xie; Maciej Kubala; Jackson J Liang; Jiandu Yang; Benoit Desjardins; Pasquale Santangeli; Rob J van der Geest; Robert Schaller; Michael Riley; Gregory Supple; David S Frankel; David Callans; Erica Zado Pac; Francis Marchlinski; Saman Nazarian
Journal:  J Cardiovasc Electrophysiol       Date:  2019-01-06

2.  2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.

Authors:  Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Saenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld
Journal:  J Interv Card Electrophysiol       Date:  2020-10       Impact factor: 1.900

Review 3.  Sudden cardiac death in patients with nonischemic cardiomyopathy.

Authors:  Brian P Betensky; Sanjay Dixit
Journal:  Indian Heart J       Date:  2014-01-06

Review 4.  Ventricular tachycardia mapping and ablation in arrhythmogenic right ventricular cardiomyopathy/dysplasia: Lessons Learned.

Authors:  Cory M Tschabrunn; Francis E Marchlinski
Journal:  World J Cardiol       Date:  2014-09-26

Review 5.  Outcomes of Catheter Ablation of Ventricular Tachycardia in the Setting of Structural Heart Disease.

Authors:  B P Betensky; F E Marchlinski
Journal:  Curr Cardiol Rep       Date:  2016-07       Impact factor: 2.931

6.  Association of regional epicardial right ventricular electrogram voltage amplitude and late gadolinium enhancement distribution on cardiac magnetic resonance in patients with arrhythmogenic right ventricular cardiomyopathy: Implications for ventricular tachycardia ablation.

Authors:  Shuanglun Xie; Benoit Desjardins; Maciej Kubala; Jackson Liang; Jiandu Yang; Rob J van der Geest; Robert Schaller; Michael Riley; David Callans; Erica Zado; Francis Marchlinski; Saman Nazarian
Journal:  Heart Rhythm       Date:  2018-03-02       Impact factor: 6.343

7.  2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.

Authors:  Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Sáenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld
Journal:  Europace       Date:  2019-08-01       Impact factor: 5.214

8.  European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population.

Authors:  Jens Cosedis Nielsen; Yenn-Jiang Lin; Marcio Jansen de Oliveira Figueiredo; Alireza Sepehri Shamloo; Alberto Alfie; Serge Boveda; Nikolaos Dagres; Dario Di Toro; Lee L Eckhardt; Kenneth Ellenbogen; Carina Hardy; Takanori Ikeda; Aparna Jaswal; Elizabeth Kaufman; Andrew Krahn; Kengo Kusano; Valentina Kutyifa; Han S Lim; Gregory Y H Lip; Santiago Nava-Townsend; Hui-Nam Pak; Gerardo Rodríguez Diez; William Sauer; Anil Saxena; Jesper Hastrup Svendsen; Diego Vanegas; Marmar Vaseghi; Arthur Wilde; T Jared Bunch; Alfred E Buxton; Gonzalo Calvimontes; Tze-Fan Chao; Lars Eckardt; Heidi Estner; Anne M Gillis; Rodrigo Isa; Josef Kautzner; Philippe Maury; Joshua D Moss; Gi-Byung Nam; Brian Olshansky; Luis Fernando Pava Molano; Mauricio Pimentel; Mukund Prabhu; Wendy S Tzou; Philipp Sommer; Janice Swampillai; Alejandro Vidal; Thomas Deneke; Gerhard Hindricks; Christophe Leclercq
Journal:  Europace       Date:  2020-08-01       Impact factor: 5.214

9.  Ventricular Tachycardia Ablation - The Right Approach for the Right Patient.

Authors:  Mouhannad M Sadek; Robert D Schaller; Gregory E Supple; David S Frankel; Michael P Riley; Mathew D Hutchinson; Fermin C Garcia; David Lin; Sanjay Dixit; Erica S Zado; David J Callans; Francis E Marchlinski
Journal:  Arrhythm Electrophysiol Rev       Date:  2014-11-29

10.  Catheter Ablation for Ventricular Arrhythmias.

Authors:  Eyal Nof; William G Stevenson; Roy M John
Journal:  Arrhythm Electrophysiol Rev       Date:  2013-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.